David Sinclair· PhD
Another more recent result, a combination of NR, which is another kind of NAD booster that we talked about a few episodes back, and pterostilbene slowed down the progression of ALS.
Loading…
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
Another more recent result, a combination of NR, which is another kind of NAD booster that we talked about a few episodes back, and pterostilbene slowed down the progression of ALS.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
This was a pretty short-term study. It showed immediate returns for ALS patients when they took this combination of NR and pterostilbene. But Lenny Guarente, who's running the study out of his lab at MIT, your former mentor there, we chatted with him this morning. He said, actually, they're now looking at a year long study so that they can see if these results continue on for a longer term for patients who are dealing with a really, really debilitating disease.
but if you look at the placebo versus the control that placebos got worse and the drug experimental most of them went up in improvement in terms of life measurements you didn't have to squint to see that result which was a nice thing
the placebo versus the control that placebos got worse and the drug experimental most of them went up in improvement in terms of life measurements you didn't have to squint to see that result which was a nice thing